Search

Search Results

1. Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study

   To determine the maximum tolerated dose (MTD) and recommended dose (RD) of orally-administered bendamustine in Japanese patients with advanced solid...

   Toshio Shimizu, Kazuhiko Nakagawa, ... Masayuki Takeda in Investigational New Drugs

   Article Open access 04 November 2022
   

2. Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies

   Purpose

   The purpose of this study was to analyze potential differences in antitumor efficacy and pharmacokinetics between intravenous (IV)...

   Megan J. Cracchiolo, Lisa Davis, ... Emmanuel Katsanis in Cancer Chemotherapy and Pharmacology

   Article 15 June 2024
   

3. A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

   Purpose

   This phase I/II clinical study was conducted to examine the safety, tolerability, pharmacokinetics, and efficacy of 10-min dosing of...

   Kenichi Ishizawa, Masahiro Yokoyama, ... Michinori Ogura in Cancer Chemotherapy and Pharmacology

   Article Open access 07 July 2022
   

4. Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors

   Background

   The glycoengineered, humanized anti-CD20 antibody obinutuzumab is indicated for previously untreated or relapsed/refractory CD20-positive...

   Yoriko Yamashita-Kashima, Keigo Yorozu, ... Yasushi Yoshimura in International Journal of Hematology

   Article 18 March 2022
   

5. Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial

   Background . Chronic lymphoblastic leukemia (CLL) is the most common adult leukemia and mainly affects the elderly. Chemoimmunotherapy still has a...

   Daobin Zhou, Wei Xu, ... Yue Lv in Investigational New Drugs

   Article 15 January 2022
   

6. Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial

   Definite cure remains exceptional in myeloma patients even after high-dose chemotherapy (HDCT) with melphalan (Mel) and autologous stem cell...

   Sarah Farag, Ulrike Bacher, ... Thomas Pabst in Bone Marrow Transplantation

   Article Open access 20 April 2022
   

7. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma

   Purpose

   Chemotherapy for the hemodialysis (HD) patient is a challenging situation because it requires special considerations including dose...

   Hajime Yasuda, Naoko Kaga, ... Miki Ando in Cancer Chemotherapy and Pharmacology

   Article 26 September 2023
   

8. Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study

   The GALLIUM study showed a progression-free survival advantage of 7% in favor of obinutuzumab vs. rituximab-based immunochemotherapies as first-line...

   Tamar Berger, Tzippy Shochat, ... Ronit Gurion in Annals of Hematology

   Article 19 June 2023

9. Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma

   Autologous stem cell transplant (ASCT) is an effective treatment for non-Hodgkin lymphoma (NHL). However, recent supply issues and toxicity of...

   Do Young Kim, Joo-seop Chung, ... Ho-** Shin in Annals of Hematology

   Article 05 February 2020
   

10. Immunosuppressants

    in Reactions Weekly

    Article 18 May 2024

11. Antineoplastics

    in Reactions Weekly

    Article 22 July 2023

12. Ibrutinib

    in Reactions Weekly

    Article 17 February 2024

13. Antineoplastics

    in Reactions Weekly

    Article 03 December 2022

14. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemia

    Ibrutinib is a first-in-class Bruton kinase inhibitor against B-cell neoplasms including Waldenström macroglobulinemia (WM). This study evaluated the...

    Koji Izutsu, Hisashi Kato, ... Ei Fujikawa in International Journal of Hematology

    Article Open access 10 April 2024
    

15. Ibrutinib/methotrexate

    in Reactions Weekly

    Article 18 November 2023

16. Antineoplastics

    in Reactions Weekly

    Article 01 October 2022

17. Acalabrutinib/ibrutinib/venetoclax

    in Reactions Weekly

    Article 11 November 2023

18. Old age in patients and vines

    Shaun R. McCann in Bone Marrow Transplantation

    Article 26 September 2022
    

19. Extranodal MALT Lymphoma in the Oral Cavity: A Series of Three Cases with Review of Literature

    Background

    Diagnosis of MALT lymphoma in the oral cavity is challenging. There is a great overlap in the histopathologic, immuno-histochemical and...

    Ramandeep Kaur, Dhanlaxmi Shetty, ... Tanuja Shet in Head and Neck Pathology

    Article 08 June 2022
    

20. A systematic review regarding the prevalence of malignancy in patients with the hyper-IgE syndrome

    The hyper-immunoglobulin E syndrome (HIES) is a primary immunodeficiency disease originally described as Job syndrome. The fundamental causative...

    Tayebeh Mohammadi, Gholamreza Azizi, ... Marzieh Tavakol in Clinical and Experimental Medicine

    Article 04 November 2023